Analysis of the application of atosiban in the fresh embryo transfer cycle in the test-tube baby program
10.3760/cma.j.cn101441-20200303-00105
- VernacularTitle:阿托西班在试管婴儿新鲜移植周期中的应用效果分析
- Author:
Lanlan CHENG
1
;
Li TAN
1
;
Zonggang FENG
1
;
Lijing WAN
1
Author Information
1. 郑州大学第二附属医院生殖医学部 450014
- Publication Type:Journal Article
- Keywords:
Atosiban;
Uterine contraction;
Fertilization in vitro;
Embryo transfer;
Intracytoplasmic sperm injection;
Clinical pregnancy rate;
Live birth rate;
Bir
- From:
Chinese Journal of Reproduction and Contraception
2021;41(2):125-130
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the application of oxytocin receptor antagonist atosiban in the fresh embryo transfer cycle of in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) program. Methods:We selected 2349 fresh embryo transfer cycles, ranging from January 2016 to December 2019 in Reproductive Medicine Center, the Second Affiliated Hospital of Zhengzhou University. Patients were randomly categorized into atosiban group (1176 cycles) and control group (1173 cycles). The related indicators and clinical outcomes were compared between the two groups.Results:The implantation rate [50.31% (1046/2079)], the clinical pregnancy rate [64.37% (757/1176)] and the live birth rate [53.17% (553/1040)] in atosiban group were remarkably higher than those of control group [39.09% (817/2090), 51.32% (602/1173), 41.01% (431/1051)], and the differences were significant statistically (all P<0.001). There were no differences in multiple pregnancy rate, multiple live birth rate, ectopic pregnancy rate and birth defect rate between the two groups (all P>0.05). Miscarriage rate of atosiban group [13.47% (102/757)] was lower than that of control group [16.44% (99/602)], but there was no significant difference ( P>0.05). Conclusion:Atosiban could inhibit uterus contraction and peristalticus to improve implantation rate, clinical pregnancy rate and live birth rate, and atosiban did not increase the risk of birth defect in offspring. Therefore, application of oxytocin receptor antagonist atosiban could improve the clinical outcome in the fresh embryo transfer cycle of IVF/ICSI.
